We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter Announces CE Mark for Hematology Analyzer

By LabMedica International staff writers
Posted on 30 Apr 2018
Print article
Image: The DxH 520 is designed to help low-volume labs enhance patient care through increased productivity with reduced costs (Photo courtesy of Beckman Coulter Diagnostics).
Image: The DxH 520 is designed to help low-volume labs enhance patient care through increased productivity with reduced costs (Photo courtesy of Beckman Coulter Diagnostics).
Beckman Coulter (Brea, CA, USA) announced achievement of CE Mark for its DxH 520 hematology analyzer, designed to help physician office laboratories deliver high-quality results with increased productivity and ease. With as little as two environmentally friendly reagents, the compact five-part differential system enhances efficiency and resource management through a comprehensive feature set that automates daily tasks. This reduces the amount of time spent on laboratory operations and frees time for patient care.

The DxH 520 complements Beckman Coulter's wide-ranging product portfolio, delivering performance and functionality to meet the needs of clinical laboratories of all sizes—from low- to ultra-high volume. The company used its time-proven flagship DxH 800 hematology solution as the predicate method for the DxH 520 system, establishing a strong correlation throughout the entire DxH line of hematology analyzers. This provides a high level of continuity of care for clinical laboratories, regardless of whether they are small- or high-volume facilities.

Laboratories with low-volume workloads are under increased pressure to deliver high-quality patient care with greater operational efficiency. The DxH 520 analyzer strengthens clinical decision-making with its proprietary dynamic-gating method that improves sample flagging, and reduces slide reviews and technical interpretation, while maintaining effective clinical sensitivity.

As an upgrade from a three-part to a five-part differential instrument, the DxH 520 analyzer gives the clinician more information by which to make decisions when assessing a patient. A robust IT and data-management package helps reduce clerical errors and inefficiencies, and allows for easy retrieval of up to 30,000 patient samples. The system’s small 17-microliter aspiration is ideal for puncture samples from infants, geriatric, oncology, and critical care patients. Closed tube aspiration capability both simplifies analysis and ensures safety for laboratory technologists by eliminating sample exposure.

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.